|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Operating lease assets with right of use, net | ||||||||||||||||||||
| Equipment, net | ||||||||||||||||||||
| Software development costs, net | ||||||||||||||||||||
| Investment in Jiangxi Myomo Medical Assistive Appliance Co. Ltd. | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Current operating lease liability | ||||||||||||||||||||
| Current operating and financing lease liability | ||||||||||||||||||||
| Income taxes payable | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Warrant derivative liability | ||||||||||||||||||||
| Current portion long term debt, net of discount of $73,871 | ||||||||||||||||||||
| Revolving credit line | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Deferred revenue, net of current portion | ||||||||||||||||||||
| Non-current operating lease liability | ||||||||||||||||||||
| Non-current operating and financing lease liability | ||||||||||||||||||||
| Long-term debt, net of discount of $2,437,757 | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Commitments and Contingencies | ||||||||||||||||||||
| Stockholders’ Equity: | ||||||||||||||||||||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding | ||||||||||||||||||||
| Common stock par value $0.0001 per share, 100,000,000 shares authorized; 39,534,884 and 38,471,383 shares issued as of June 30, 2026 and December 31, 2025, respectively; and 39,534,857 and 38,471,356 shares outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Treasury stock, 27 shares at cost | ||||||||||||||||||||
| Total Stockholders’ Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Equity | ||||||||||||||||||||
Loading...
